Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows


WOBURN, Mass., Nov. 15, 2017 /PRNewswire/ -- Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands for high-throughput and low-input library preparation.  By using the oneTUBE-10 offering, transfer steps within the NGS library prep workflow have been eliminated from mechanical DNA shearing (using Covaris' Adaptive Focused Acoustics® (AFA®) technology) through end repair, A-tailing, ligation, and SPRI clean-up.  The oneTUBE-10 product is specifically designed for use with Covaris' AFA technology for DNA shearing at volumes ranging from 10 to 50 µL, achieving highly accurate and reproducible results. 

This new AFA vessel, is made of an engineered polymer for low impedance and efficient transmission of acoustic energy.  oneTUBE-10 effectively controls acoustic cavitation to enable reproducible and precisely-tuned hydrodynamic shear forces.   Designed to SLAS standards, oneTUBE-10 is compatible with standard heat blocks, magnets, and thermocyclers.  oneTUBE-10 can be used on any liquid handling platform, providing a universal solution for streamlining NGS workflows.  Paired with the LE220-plus (Covaris' newest Focused-ultrasonicator), NGS workflows are easily standardized by integration with high-throughput laboratory automation.

Covaris Founder and CEO, Jim Laugharn, said, "oneTUBE-10 is a game-changer for NGS workflows.  The combination of the Covaris AFA-energetics, the process behind the industry gold standard for robust, random, and unbiased DNA shearing, with a uniquely engineered polymer consumable enables highly automated library preparation, nucleic acid extraction, and additional applications in a single tube.  The improved workflow possibilities are unlimited!"

Future applications of oneTUBE-10 include FFPE extraction, enhanced ligation enzymatic reactions, and other biomolecular processes utilizing the Covaris technology.  AFA can now be applied at various steps including bead binding, mixing, and elution, while scaling down to low volumes.  Additionally, oneTUBE-10 product iterations will include an 8-strip format and will scale up to 384 well formats and beyond.

About Covaris, Inc.
Covaris is a recognized industry innovator in preanalytical sample preparation workflows involving sample stabilization, extraction, and processing.  Leveraging its patented Adaptive Focused Acoustics (AFA) technology and novel engineering solutions, Covaris has developed comprehensive packages of instrumentation, applications, reagents, and consumables to address the increasing sensitivity requirements of analytical technologies such as NGS and mass spectrometry.  Covaris Focused-ultrasonicators are recommended by all major NGS platform providers, and are used by leading Genome Centers worldwide.  The Covaris AFA process is extensively cited in peer-reviewed research articles on DNA fragmentation, ChIP, FFPE nucleic acid extraction, metabolomics, small molecule extraction, proteomics, and nanoemulsion formulation.  For more information, please visit: www.covaris.com.

SOURCE Covaris, Inc.


These press releases may also interest you

at 23:00
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

at 23:00
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

at 22:33
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....



News published on and distributed by: